Singapore-based biotech company MiRXES, a developer of RNA-powered cancer early detection tests, has opened a Hong Kong office headed by a former healthcare executive in its bid to expand to the Chinese market.
The company said Martin Law would spearhead the move to “explore partnerships in providing accurate, affordable and accessible cancer early detection to the Hong Kong and Greater Bay Area communities”.
It is MiRXES sixth office, the company said, adding that it would accelerate its pipeline development and “intensify commercial expansion” following a $87 million fundraising last year.
“Backed by its miRNA PCR technology, strong clinical pipeline, and state-of-the-art manufacturing and laboratory infrastructure, MiRXES is well-positioned to deliver holistic cancer early detection solutions,” the company said in a statement.
Law’s initial focus will be on hiring of key talents for MiRXES Hong Kong, as well as developing marketing and communications plans to increase brand awareness and product recognition.
The company said it would attempt to forge regional academic and clinical institutions.
“Hong Kong is an excellent starting base for MiRXES’s foray into the Greater Bay Area given its accessibility and connection to the surrounding countries,” Zhou Lifan, the company’s CEO and co-founder said.
“Both its public and private sectors have shown great support to the biotechnology industry, and Hong Kong’s capital market is mature and active, making it highly attractive for MiRXES to enter.”
Law was previously the chief financial officer of Hong Kong-listed EC Healthcare Group, Hong Kong’s largest non-hospital medical service provider, which operates 90 clinics providing medical and healthcare services.
“Hong Kong has an increased awareness of preventive and precision healthcare over the last 10 years, activated and supported by promotions from both government and private sectors,” Law said.
“This is an opportune time to enter Hong Kong and enable MiRXES’s proprietary RNA technology used in its disease early detection solutions to benefit the people in both Hong Kong and the Greater Bay Area.”
- George Russell
READ MORE:
US Experts to Evaluate Chinese Lung Cancer Therapy
Fukushima Nuclear Operator Sued over Thyroid Cancer Cases
China Fund Managers Pile Into Plunging Healthcare Sector
